This inventor holds 2 USPTO granted patents. Top assignees: Adjutec Pharma as, Other. Active years: 2021-2024.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2021-2024
Title: Ole Andreas Løchen Økstad: Innovator in Pharmaceutical Chemistry
Introduction
Ole Andreas Løchen Økstad is a notable inventor based in Moss, Norway. He has made significant contributions to the field of pharmaceutical chemistry, particularly in the development of compounds for treating cancer and bacterial diseases. With a total of 2 patents, Økstad's work is recognized for its potential impact on medical treatments.
Latest Patents
Økstad's latest patents include innovative methods and compositions aimed at combating serious health issues. One of his patents focuses on substituted phenazines and methods of treating cancer and bacterial diseases. This patent describes a combination product that includes a carbapenem and a specific compound, along with a pharmaceutical composition that utilizes this combination for treating bacterial or fungal infections. Another patent also centers on substituted phenazines, detailing compounds and pharmaceutical compositions that can be used in treatment methods.
Career Highlights
Throughout his career, Økstad has worked with various companies, including Adjutec Pharma AS. His expertise in pharmaceutical chemistry has allowed him to contribute to advancements in drug development and treatment methodologies.
Collaborations
Økstad has collaborated with several professionals in his field, including Pål Rongved and Ove Alexander Høgmoen Åstrand. These collaborations have likely enhanced the scope and impact of his research and innovations.
Conclusion
Ole Andreas Løchen Økstad is a distinguished inventor whose work in pharmaceutical chemistry continues to influence the development of treatments for critical health conditions. His patents reflect a commitment to advancing medical science and improving patient outcomes.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile